Thiotepa (Thiotepa) Patent Expiration, LOE Window & CMS Spending

Thiotepa (Thiotepa) by Amgen: Off-Patent Genericized (AB Competition), 2 AB generics, $10K 2024 CMS Part D & Medicaid spend, and $2,350 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayN011683 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$10K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$10K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,350 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.